<?xml version="1.0" encoding="utf-8"?>
<journal>
<title>Journal of Medical Microbiology and Infectious Diseases</title>
<title_fa>Journal of Medical Microbiology and Infectious Diseases</title_fa>
<short_title>JoMMID</short_title>
<subject>Medical Sciences</subject>
<web_url>http://jommid.pasteur.ac.ir</web_url>
<journal_hbi_system_id>1</journal_hbi_system_id>
<journal_hbi_system_user>admin</journal_hbi_system_user>
<journal_id_issn>2345-5349</journal_id_issn>
<journal_id_issn_online>2345-5330</journal_id_issn_online>
<journal_id_pii>8</journal_id_pii>
<journal_id_doi>10.61882/JoMMID</journal_id_doi>
<journal_id_iranmedex></journal_id_iranmedex>
<journal_id_magiran></journal_id_magiran>
<journal_id_sid>14</journal_id_sid>
<journal_id_nlai>8888</journal_id_nlai>
<journal_id_science>13</journal_id_science>
<language>en</language>
<pubdate>
	<type>jalali</type>
	<year>1405</year>
	<month>6</month>
	<day>1</day>
</pubdate>
<pubdate>
	<type>gregorian</type>
	<year>2026</year>
	<month>9</month>
	<day>1</day>
</pubdate>
<volume>14</volume>
<number>3</number>
<publish_type>online</publish_type>
<publish_edition>1</publish_edition>
<article_type>fulltext</article_type>
<articleset>
	<article>


	<language>en</language>
	<article_id_doi></article_id_doi>
	<title_fa></title_fa>
	<title>Therapeutic DNA Vaccines Targeting HPV E6 and E7 Oncoproteins: Current Status, Enhancement Strategies, and Clinical Progress</title>
	<subject_fa>Immune responses, deficiencies and vaccine candidates </subject_fa>
	<subject>Immune responses, deficiencies and vaccine candidates </subject>
	<content_type_fa>Review article</content_type_fa>
	<content_type>Review article</content_type>
	<abstract_fa></abstract_fa>
	<abstract>&lt;div style=&quot;text-align: justify;&quot;&gt;&lt;span style=&quot;font-size:10.0pt&quot;&gt;&lt;span style=&quot;line-height:107%&quot;&gt;&lt;span new=&quot;&quot; roman=&quot;&quot; style=&quot;font-family:&quot; times=&quot;&quot;&gt;Human papillomavirus (HPV) infection&lt;b&gt; &lt;/b&gt;is highly prevalent worldwide and causes a substantial burden of anogenital and oropharyngeal disease. Although most infections resolve spontaneously, persistent infection with oncogenic HPV types can cause cervical and other HPV-associated&lt;b&gt; &lt;/b&gt;cancers. The E6 and E7 oncoproteins sustain the malignant phenotype by disrupting p53- and&lt;b&gt; &lt;/b&gt;retinoblastoma-associated tumor-suppressive pathways, respectively. Prophylactic L1 virus-like particle (VLP) vaccines prevent new infections but do not eliminate established HPV infections or HPV-associated lesions. Therapeutic DNA vaccines encoding E6 and E7 are therefore under investigation to induce antigen-specific cellular immunity against infected and transformed cells. These plasmid-based vaccines offer manufacturing flexibility, relative stability, and opportunities for repeated administration, but their clinical performance can be limited by inefficient delivery, antigen presentation, and immunosuppressive tumor microenvironments. This narrative review examines HPV biology and host immunity, the design and mechanisms of E6/E7 DNA vaccines, and&lt;b&gt; &lt;/b&gt;approaches to improve their immunogenicity, including antigen engineering, codon optimization, dendritic cell targeting, electroporation, and combination immunotherapy. We critically summarize preclinical and clinical findings, distinguish DNA vaccines from other therapeutic platforms, and discuss the remaining challenges to clinical translation. Although several DNA-vaccine candidates have shown immunogenicity and activity against cervical precancer, convincing efficacy in advanced malignancies and broad clinical implementation remain unestablished.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;</abstract>
	<keyword_fa></keyword_fa>
	<keyword>Human papillomavirus, Cervical intraepithelial neoplasia, DNA vaccine, Therapeutic vaccination, E6 and E7, Antigen presentation</keyword>
	<start_page>0</start_page>
	<end_page>0</end_page>
	<web_url>http://jommid.pasteur.ac.ir/browse.php?a_code=A-10-632-7&amp;slc_lang=en&amp;sid=1</web_url>


<author_list>
	<author>
	<first_name>Ali</first_name>
	<middle_name></middle_name>
	<last_name>Hojaji</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code></code>
	<orcid>0000-0002-5271-8327</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Department of Genetics, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>Soheil</first_name>
	<middle_name></middle_name>
	<last_name>Shajari</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code></code>
	<orcid>0009-0009-9174-7823</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Department of Biotechnology, Faculty of Biological Science and Technology, University of Isfahan, Isfahan, Iran</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>Azam</first_name>
	<middle_name></middle_name>
	<last_name>Bolhassani</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email>A_bolhasani@pasteur.ac.ir</email>
	<code></code>
	<orcid>0000-0001-7363-7406</orcid>
	<coreauthor>Yes
</coreauthor>
	<affiliation>Department of Hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


</author_list>


	</article>
</articleset>
</journal>
